SCHEDULE 13D/A: Farallon Capital Reduces Stake in Exelixis, Discloses Significant Share Sales
Schedule 13D Amendment
Farallon Capital Management and its affiliated entities have filed an amended Schedule 13D, revealing a reduction in their beneficial ownership of Exelixis, Inc. common stock through a series of open-market sales.
Summary
- Farallon Capital Partners, L.P. and its related entities, including Farallon Capital Management, L.L.C., have filed Amendment No. 6 to their Schedule 13D regarding their holdings in EXELIXIS, INC.
- The filing indicates that as of May 5, 2025, there were 272,708,280 Shares of Exelixis common stock outstanding.
- Farallon Healthcare Partners Master, L.P. is reported to beneficially own 10,130,194 shares, representing 3.7% of the class.
- Farallon Partners, L.L.C. is reported to beneficially own 17,991,186 shares, representing 6.6% of the class.
- Several individual reporting persons, including Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, each report shared voting and dispositive power over 18,635,500 shares, representing 6.8% of the class.
- The amendment details numerous open-market sales of Exelixis shares by various Farallon funds between April 7, 2025, and May 20, 2025.
- Sale prices for these transactions ranged from approximately $33.36 to $47.59 per share.
Sentiment
Score: 4
Explanation: The document reports significant selling activity by a major institutional investor, which is generally perceived as a negative signal by the market, indicating a reduction in confidence or a reallocation of capital.
Negatives
- A significant institutional investor, Farallon Capital, has reduced its stake in Exelixis through a series of open-market sales over the past sixty days.
- The aggregate number of shares sold across all Farallon entities and individuals indicates a notable decrease in their overall beneficial ownership.
Future Outlook
NA
Industry Context
This filing reflects a change in a major institutional investor's position in a biotechnology company. Such changes can sometimes signal shifts in investor sentiment towards the company or the broader pharmaceutical/biotech sector, though the document itself does not provide the rationale for the sales.
Stakeholder Impact
- Shareholders: The reduction in stake by a prominent institutional investor could lead to negative sentiment and potential downward pressure on the stock price.
- Investment Professionals: Provides updated information on a significant investor's position, which may influence their own investment decisions or analysis of Exelixis.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Start date of the 60-day trading history for share sales by Farallon Funds. |
| 05/05/2025 | Date as of which 272,708,280 Shares of Exelixis, Inc. were reported outstanding in the company's Form 10-Q. |
| 05/13/2025 | Date Exelixis, Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 05/16/2025 | Date of event which required the filing of this Schedule 13D Amendment No. 6. |
| 05/20/2025 | End date of the 60-day trading history for share sales by Farallon Funds and filing date of the Schedule 13D Amendment No. 6. |
Keywords
Exelixis, Farallon Capital, Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.